Daesung Microbiological Labs. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 13, 2022 at 08:32 pm EST
Share
Daesung Microbiological Labs. Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 4,956.12 million compared to KRW 5,438.62 million a year ago. Net loss was KRW 16.28 million compared to KRW 335 million a year ago. Basic loss per share from continuing operations was KRW 4 compared to KRW 88 a year ago. Basic loss per share was KRW 4 compared to KRW 88 a year ago.
For the nine months, negative sales was KRW 0.00034 million compared to sales of KRW 0.00021 million a year ago. Net income was KRW 1,739.45 million compared to KRW 112.63 million a year ago. Basic earnings per share from continuing operations was KRW 457 compared to KRW 29 a year ago. Basic earnings per share was KRW 457 compared to KRW 29 a year ago.
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. is a Korea-based company mainly engaged in the manufacture of animal pharmaceuticals. The Companyâs products consist of vaccines, antibiotics, antibacterials, anthelminthics, mastitis ointments, disinfectants, probiotics and enzyme products, teat dipping disinfectants, metabolites, nutrients, and biologicals used for prevention and treatment of diseases for cattle, swine, poultries and canines. The Company distributes its products within domestic market and to overseas markets, including Southeast Asia, Middle East and Africa.
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. 
